A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care - GS-US-563-5926

Start Date28 Jan 2025

Sponsor / Collaborator

Gilead Sciences, Inc.

CTIS2024-514046-37-00

/ RecruitingPhase 3

A Phase 3, Randomized, Double-Blind, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir (B/F/TAF). - GS-US-563-5925

Start Date22 Jan 2025

Sponsor / Collaborator

Gilead Sciences, Inc.

NCT06811246

/ CompletedPhase 1

An Open-Label Study to Evaluate the Effect of Multiple Doses of Lamivudine on the Single Dose Pharmacokinetics of Islatravir in Healthy Participants

The goal of this study is to learn what happens to the medication islatravir (ISL), in a healthy person's body over time--called a pharmacokinetic (PK) study. Researchers want to compare the amount of islatravir in the blood when it is taken alone as a single dose and when it is taken with multiple doses of another medication called lamivudine (3TC).

Start Date07 Feb 2024

Sponsor / Collaborator

Merck Sharp & Dohme LLC

100 Clinical Results associated with Islatravir

100 Translational Medicine associated with Islatravir

100 Patents (Medical) associated with Islatravir

487

Literatures (Medical) associated with Islatravir

01 Oct 2025·MICROBIAL PATHOGENESIS

Isoliquiritin suppressed LPS/CuSO4-induced pro-inflammatory response on RAW264.7 cell and zebrafish

Article

Author: Zhang, Xiao-Huan ; He, Ming-Fang ; Zhang, Fei-Xiang ; Cai, Jing ; Wu, Jia-Qi ; Bin, Xin-Ni

AIM OF THIS STUDY:

Isoliquiritin (ISL) as one of bioactive flavonoid from licorice was reported to have bioactivities. This study aims to evaluate the anti-inflammatory properties of ISL on RAW264.7 cells and zebrafish and reveal its possible anti-inflammatory mechanism.

MATERIAL AND METHODS:

The anti-inflammatory activity of ISL was measured by LPS-induced RAW264.7 cells and CuSO₄-induced zebrafish models. The accumulation of reactive oxygen species (ROS) and nitric oxide (NO) in RAW264.7 cells and zebrafish were detected by H2DCFDA fluorescent probe and nitric oxide detection kit, respectively. The nuclear translocation of NF-κB p65 in LPS-induced RAW264.7 cells was detected by immunofluorescence assay. The protein levels of IL-1β, IL-6 and TNF-α in LPS-induced RAW264.7 cells were detected by ELISA assay. The recruitment of neutrophils and macrophages was observed using fluorescence microscope and quantified by ImageJ in the zebrafish inflammatory model. The expression level of inflammation-related cytokines was analyzed by quantitative real-time PCR (qRT-PCR).

RESULTS:

ISL reduced the accumulation of ROS and NO in LPS-induced RAW264.7 cells and CuSO₄-induced zebrafish inflammatory models, inhibited the nuclear translocation of NF-κB p65 and reduced the release of IL-1β, IL-6 and TNF-α in LPS-induced RAW264.7 cells. Furthermore, the decrease in inflammatory cell infiltration and neutrophil migration suggests the occurrence of inflammatory reactions and the anti-inflammatory effect of ISL in vivo. ISL reduced the expressions of inflammation-related cytokines in LPS-induced RAW264.7 cells and zebrafish inflammatory models.

CONCLUSION:

ISL exerts significant anti-inflammatory effects by reducing the production of ROS and NO, inhibiting the nuclear translocation of NF-κB p65, and inhibiting the expression of inflammatory-related factors. And it is a potential treatment option for inflammatory-related diseases.

01 Sep 2025·PHYTOMEDICINE

Isoliquiritigenin alleviates abnormal sarcomere contraction and inflammation in myofascial trigger points via the IL‐17RA/Act1/p38 pathway in rats

Article

Author: Qi, Tian ; He, Ren ; Li, Xiaoyue ; Lin, Pengyu ; Liu, Yu ; Zhou, Lingwei ; Qi, Feng ; Yang, Shaozhong ; Chen, Qinghe ; Li, Xuan

BACKGROUND:

Myofascial trigger points (MTrPs) are a primary cause of myofascial pain syndrome. Current studies suggest that MTrPs consist of persistent sarcomere contraction and an inflammatory microenvironment. IL-17 has been implicated in the progression of inflammation. However, its expression of IL-17 in MTrPs and the underlying mechanisms remain unclear.

PURPOSE:

This study aimed to characterise IL-17 signalling and elucidate the associated molecular mechanisms in the context of MTrPs, and evaluate the therapeutic effects of isoliquiritigenin (ISL) on MTrPs.

METHODS:

We examined IL-17A signalling expression using immunohistochemistry, reverse transcription-quantitative polymerase chain reaction and western blot analysis in MTrPs rat. Haematoxylin and eosin staining and transmission electron microscopy were used to assess muscle fibre and sarcomere morphology. The Randall-Selitto test was employed to evaluate pain-like behaviours in rats. Dihydroethidium staining, JC-1 assay, and ATP quantification were used to assess inflammation-associated mitochondrial function in vitro and in vivo. Additionally, molecular docking, cellular thermal shift, and drug affinity responsive target stability assays were conducted to examine the interaction between ISL and the IL-17 receptor subunit A (IL-17RA) protein.

RESULTS:

IL-17A and IL-17RA were significantly expressed in rats with MTrPs. These rats exhibited elevated oxidative stress level and reduced ATP production. Studies on IL-17A stimulated myotubes and gastrocnemius muscle indicated that IL-17RA signalling contributes to inflammation, abnormal sarcomere contraction and mitochondrial dysfunction in MTrPs. Lentivirus-mediated IL-17RA knockdown in the rats further confirmed these findings. Inhibition of the mitogen-activated protein kinase p38 and subsequent rescue experiments highlighted the critical role of IL-17RA/Act1/p38 signalling. Notably, molecular docking and validation experiments revealed that ISL binds to and inhibits IL-17RA, thereby disrupting IL-17RA/Act1/p38 signalling, and ultimately suppressing the maintenance of MTrPs.

CONCLUSION:

This study demonstrates that ISL ameliorates sarcomere contraction and inflammatory responses by inhibiting the IL-17RA/Act1/p38 signalling pathway in rats with MTrPs, highlighting its potential as a novel therapeutic strategy for myofascial pain syndrome (MPS).

01 Aug 2025·CANCER LETTERS

Isoliquiritigenin reduces brain metastasis by circNAV3-ST6GALNAC5-EGFR axis in triple-negative breast cancer

Article

Author: Zhang, Jinhui ; Xiao, Xiangsheng ; Xie, Yi ; Li, Xing ; Huang, Guoxian ; Tang, Hailin ; Tang, Yuhui ; Xie, Jindong ; Luo, Yongzhou ; Song, Cailu ; Zhang, Chi ; Shuang, Zeyu

Brain metastasis (BM) is a serious complication of increasing incidence in patients with advanced breast cancer, which is characterized by swift deterioration in quality of life with few efficient therapy strategies. There is an urgent clinical requirement to devise potent therapeutic strategies for the prevention and management of brain metastases. Here, we report isoliquiritigenin (ISL), a key bioactive substance extracted from licorice root, which effectively inhibited triple-negative breast cancer (TNBC) brain metastasis (BM) by downregulation of circNAV3. CircRNAs expression analyses and functional studies, coupled with clinical significance investigations identified circNAV3 as a key molecule promoting TNBC BM. Functionally, circNAV3 could promote proliferation, migration, invasion, angiogenesis and capacity to penetrate the blood-brain barrier of TNBC cells. Mechanistically, circNAV3 could competitively bind with miR-4262, hence intercepting the suppressive effect of miR-4262 on ST6GALNAC5. Subsequently, this interplay enhanced EGFR sialylation and activation, initiating the PI3K/Akt pathway and ultimately fostering the development of TNBC brain metastases. In conclusion, our research establishes that ISL impede the initiation and advancement of TNBC brain metastasis by modulation of circNAV3/miR-4262/ST6GALNAC5/EGFR axis, laying a theoretical groundwork for the therapeutic use of ISL in this scenario.

News (Medical) associated with Islatravir

15 Jul 2025

·www.biospace.com

Gilead, GSK/ViiV, Merck Present New HIV PrEP Frontiers at IAS25

iStock, MotionIsland HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the heels of the landmark Yeztugo approval. The HIV space saw a historic moment last month with the approval of Gilead’s Yeztugo, a long-acting preventive injectable for HIV. Yeztugo isn’t the first long-acting pre-exposure prophylactic option—ViiV Healthcare’s Apretude also provides prolonged protection—but Gilead’s option only needs to be dosed twice a year, giving patients a more convenient option. Analysts and global health authorities have lauded the approval, with Mizuho at the time saying that Yeztugo “has the potential to ‘redefine’ the PrEP market.” The annual meeting of the International AIDS Society (IAS) is riding these tailwinds. The conference, currently being held in Kigali, Rwanda, is headlined by pharmas with some of the biggest developments in the field presenting the latest developments in their pipelines. BioSpace looks at some of the most interesting presentations here. Gilead Broadens Evidence Base for Yeztugo in Pregnancy and Young People On Thursday, Gilead will present additional data from its Phase III PURPOSE program for Yeztugo, showing that the drug was “efficacious and well tolerated” when used in different vulnerable patient populations. In the PURPOSE 1 study, which enrolled cisgender women and adolescent girls across sub-Saharan Africa , none of the 184 pregnant and lactating women treated with Yeztugo contracted HIV, according to a press announcement on Monday. The twice-yearly PrEP injection was also safe in these women, with no notable differences in adverse events compared with non-pregnant women. Infant exposure through breastfeeding was also “minimal,” according to Gilead. Meanwhile, data from PURPOSE 1 and PURPOSE 2—which together encompass a geographically and gender diverse population—showed that Yeztugo maintained its efficacy in young people aged 16 through 25 years. In this age group, only two cases of HIV were detected after Yeztugo treatment. Gilead did not say the size of the patient population in these trials. Gilead also presented modeling data which suggest that Yeztugo, when given at a slightly altered dosing regimen, can retain its efficacy in patients with tuberculosis, who often take other medications that can otherwise interfere with PrEP’s overall activity. Yeztugo is currently only approved in the U.S., but Gilead is working on securing regulatory clearances around the world, including South Africa. The pharma last week signed an agreement with the Global Fund to provide the HIV prophylactic to low- and middle-income countries at the same time as in high-income countries. A spokesperson at the time declined to disclose specific pricing details for Yeztugo under the Global Fund partnership, but told BioSpace that it will provide the product to the program at no profit to Gilead. ViiV Finds Patients ‘Happy’ to Switch to Apretude from Daily Oral PrEP ViiV unveiled data from the PILLAR and EBONI implementation trials showing that the use of Apretude, a long acting PrEP given every other month, is both acceptable and feasible for patients across different demographic groups, including transgender men, Black women and men who have sex with men (MSM). Apretude was the first injectable long acting HIV PrEP, approved in the US in 2021 . Viiv is a joint venture between GSK, Pfizer and Shionogi that is focued on HIV care. EBONI, which focused on Black cis- and transgender women, found Apretude to be “highly appropriate” and “feasible” for the prevention of HIV in this population, as per Monday’s release. PILLAR, meanwhile, enrolled MSM and transgender men, among whom 95% reported being “happy” with switching from oral PrEP medications to Apretude. ViiV additionally presented data from several real-world studies, showing that the combination of cabotegravir and rilpivirine—marketed as the injectable drug Cabenuva in the U.S.—not only sustains viral suppression in patients but also improves their overall experience. For instance, results in the Phase IIIb VOLITION study showed that 89% of patients with HIV who had reached viral suppression chose to switch to Cabenuva from oral daily pills. Largely, patients opted for Cabenuva so they wouldn’t have to worry about missing a dose and so they wouldn’t have to bring their medication all the time. Cabenuva can be dosed monthly or every two months, according to its label . Meanwhile, results from the two-year prospective observational study BEYOND found that of 308 patients who decided to switch to Cabenuva, 97% were able to maintain viral suppression at 24 months. Merck Pushes Monthly PrEP Pill to Phase III Merck announced on Monday that it will launch the Phase III EXPrESSIVE program to study MK-8527, a once-monthly and orally available nucleoside reverse transcriptase translocation inhibitor to prevent HIV infection. The program will include EXPrESSIVE-11, which will test the PrEP candidate in more than 8,500 high-risk participants across 16 countries. That trial is set to start enrolling in August. Meanwhile, the EXPrESSIVE-10 study will focus on women and adolescents in sub-Saharan Africa and is set to start recruiting “in the next few months,” as per Monday’s release. Phase II data for MK-8527, which will be presented at IAS 2025 on Wednesday, is supporting the advancement of the drug into late-stage development, according to Merck, with encouraging pharmacokinetic and safety findings. 350 people with low risk of HIV-1 exposure participated in the mid-stage study. The EXPrESSIVE program represents Merck’s comeback in the late-stage PrEP arena after discontinuing the prophylaxis program for oral islatravir in September 2022, after safety concerns led the company to suspend dosing in a Phase II study in November 2021. Like MK-8527, the pharma was proposing islatravir as a once-monthly oral option to prevent HIV infection. However, Merck continued to assess islatravir as a therapeutic option for patients with HIV in combination with another HIV drug called doravirine. The FDA last week accepted a new drug application for this combo regimen for adults with virologically suppressed HIV-1.

Phase 3Phase 2Clinical ResultDrug Approval

14 Jul 2025

·endpoints.news

Merck sends new monthly oral PrEP to Phase 3 after earlier islatravir setback

KIGALI, RWANDA — Three years after a safety disappointment halted earlier plans for a once-monthly HIV PrEP candidate, Merck is back in the late stages of development with a next-generation effort. The New Jersey company said Monday that it plans to move into Phase 3 next month with a once-monthly oral prevention tool for HIV, known as MK-8527. While current PrEP pills must be taken every day, MK-8527’s monthly dosing schedule would represent a significant advance for oral HIV preventatives. The drug is a nucleoside reverse transcriptase translocation inhibitor, or NRTTI. It’s an improved, follow-up version to Merck’s other NRTTI, islatravir, which the pharmaceutical maker scrapped for development as an HIV prophylactic after safety issues. MK-8527 didn’t have those same concerns, according to Phase 2 data presented Monday at the biennial International AIDS Society conference on HIV Science, taking place in Kigali, Rwanda. “We’re not seeing an issue with lymphocytes and CD4 cells” with MK-8527, Luisa Stamm, associate VP and section head for HIV at Merck, said in an interview with Endpoints News . There were “no clinically meaningful changes” in lab tests, including total lymphocyte and CD4 T-cell counts, the company said. A total of 350 people at low risk for HIV were enrolled in the placebo-controlled study , including 51.4% white individuals, 41.4% Black participants and 2.3% Asian enrollees. About 94% of participants received all six monthly doses. “The top-level, bottom-line is that it was safe and well tolerated,” Ken Mayer, presenting author of the study, said in an interview with Endpoints on the sidelines of IAS. While Merck scrapped development of islatravir for PrEP in 2022, it carried forward with the drug as an HIV treatment. The company modified the dosing regimen and ran new clinical trials, and the FDA accepted a new application for a two-drug regimen of islatravir and doravirine as a once-daily, oral treatment for adults with HIV-1. An approval decision is slated for April 28, 2026, Merck said last week. Like islatravir, MK-8527 is also an NRTTI. “It inhibits both transcription and translocation, so that’s why it’s particularly potent. One molecule inhibits two steps of the virus life cycle,” Mayer said. The long period between doses has to do with how the body metabolizes the drug. “It’s converted to its active form intracellularly, and that triphosphate has a very long half-life, which enables this monthly dosing,” Stamm said. “Half-life is about 10 days, so that really allows us to predict with that low 11 mg dose that we’ll be above that target efficacy threshold.” Next month, Merck plans to dose the first participant in a 4,390-person Phase 3 trial in people at risk for HIV. The EXPrESSIVE-11 trial will include people in more than 15 countries and will test MK-8527 against daily Truvada, also known generically as emtricitabine/tenofovir disoproxil fumarate, or FTC/DTF. “When we think about globally, FTC/TDF is the most accessible standard of care, so we thought that was the first good reason” for making it the comparator, Stamm said. The second main reason, she said, was that Merck wanted to do a direct comparison to another oral drug, rather than long-acting injectables, which have shown strong results in preventing PrEP. The US federal trials database lists an estimated study completion of October 2027, but Stamm cautioned that the trial will be event-driven, rather than time-driven. Later this fall, Merck also plans to begin a separate Phase 3 of MK-8527 in conjunction with the Gates Foundation, which is one of the largest funders of HIV work globally and has been a partner of Merck on other programs, including islatravir. That Phase 3 trial, called EXPrESSIVE-10, will include women and adolescent girls in Kenya, South Africa, and Uganda. For the sub-Saharan Africa study, the Gates Foundation will provide grant funding to the International Clinical Research Center within the University of Washington Department of Global Health and in partnership with the University of Alabama at Birmingham. The move into late-stage testing with MK-8527 could be a pivotal moment for preventing new acquisitions of HIV. Despite the availability of daily oral PrEP pills and long-acting injectables, the world is well behind global organizations’ targets for PrEP uptake. The United Nations had a goal of getting at least 21.2 million annual PrEP users in 2025. Nine million initiations have been made, the AIDS Vaccine Advocacy Coalition (AVAC) said in a June report . “We know from the contraception literature that the more clinical options you offer people, the larger the number of people who will be accessing at least one option. People cycle through things,” Mayer said. If successful, Merck’s tablet would provide a potentially easier-to-access tool than the two approved long-acting injectables. GSK’s ViiV Healthcare markets a once-every-two-month PrEP injectable called Apretude, and Gilead secured FDA approval for a twice-yearly shot, called Yeztugo, this summer. For nearly a decade, daily pills were the only PrEP option prior to the approval of the injectable Apretude in late 2021. A tablet could come with fewer manufacturing challenges, and would be easier to take than an injection. But questions remain as to what requirements would be put in place for HIV testing frequency and how many of the monthly tablets people would be able to get from the pharmacy at one time. “There are a lot of ways that we could make it a lot easier for people and make it appealing, and there are a lot of ways that the crazy system in the US could make it very difficult,” Mayer said. As Merck runs its Phase 3 trials, a key question will be access and cost, should the tablet pass muster. “We could be on the verge of an HIV prevention revolution that reduces new infections towards epidemic control—if the world comes together again to overcome monopolies, drive down prices, and ensure everyone who could benefit has access to these new, highly effective prevention tools,” Winnie Byanyima, UNAIDS executive director, said in an annual report released last week. Byanyima appears to have directly pointed to Merck’s MK-8527 in her remarks, referring to the potential of monthly tablets potentially becoming a “reality” to prevent HIV “within the next few years.” Price has also been an issue. Advocates have criticized the price of ViiV’s Apretude and Gilead’s Yeztugo. ViiV has a generic manufacturing licensing agreement via the Medicines Patent Pool, or MPP, a United Nations-backed organization that helps countries secure access to critical medicines. Gilead has a pact with six generic manufacturers, but not by way of MPP. Merck is already pondering how MK-8527 could be rolled out. “It’s not too early to be planning for this. We’ve been thinking about it a lot, also looking at what others are doing,” Stamm said. Merck has a history of working with governments and organizations like the Gates Foundation for “ensuring broad and sustainable accessibility,” Stamm said. As an example, she pointed to Merck’s voluntary licensing agreement with MPP for the investigational antiviral molnupiravir during the Covid-19 pandemic. “There we were really successful, through voluntary licensing, to get supply available for high- and middle-income countries essentially at the same time,” Stamm said. “I think we’ll take the same approach, is our early thoughts here, when we’re thinking about 8527.”

Phase 3Drug ApprovalVaccinePhase 2License out/in

14 Jul 2025

·firstwordpharma.com

Merck & Co. moves once-monthly HIV prevention pill into Phase III

Merck & Co. is diving into the next generation of HIV prevention with a once-a-month pill, entering late-stage trials just weeks after Gilead Sciences' long-acting injection won FDA approval. The move potentially sets up a nascent rivalry between different dosing approaches, with Merck's contender, MK-8527, potentially offering an alternative, non-injectable option for pre-exposure prophylaxis (PrEP).The decision to advance MK-8527, a nucleoside reverse transcriptase translocation inhibitor, was supported by a Phase II study involving 350 adults ages 18 through 65. The trial showed similar adverse event rates between the drug and placebo groups, with no clinically meaningful changes in laboratory tests including total lymphocyte and CD4 T-cell counts. Moreover, Merck said pharmacokinetics data from the study, to be detailed in a late-breaker presentation Wednesday at the International AIDS Society (IAS) conference, demonstrated that both MK-8527 and its active form MK-8527-TP support once-monthly dosing for prevention.The new Phase III EXPrESSIVE programme includes two large-scale trials. EXPrESSIVE-11 will enroll 4390 sexually active people across 16 countries beginning in August, comparing MK-8527 to daily treatment with Gilead's Truvada (emtricitabine/tenofovir disoproxil fumarate). EXPrESSIVE-10, conducted in partnership with the Gates Foundation, will focus on 4580 women ages 16 to 30 in Kenya, South Africa and Uganda, with enrollment starting "in the next few months," according to Merck."With only 18% of global PrEP need currently met, there is a clear and urgent need for options like MK-8527 that may offer the ability to prevent infection," said Trevor Mundel, president of global health at the Gates Foundation, in a release Monday.The entry of MK-8527 into Phase III comes on the heels of what Gilead CEO Daniel O'Day described as the "historic" FDA approval of the company's long-acting HIV-1 capsid inhibitor Yeztugo (lenacapavir) last month. The twice-yearly injection demonstrated near-complete protection in clinical trials, with no HIV infections reported in one study and just two cases among 2180 participants in another.Early feedback suggests strong enthusiasm for the longer-acting option. The World Health Organization (WHO) on Monday recommended the use of Yeztugo as a "powerful tool" to prevent HIV infections. Plus, results from a recent FirstWord physician poll showed that 89% of respondents expect Yeztugo's twice-yearly dosing to improve patient adherence and satisfaction compared to current alternatives. For more, see – Physician Views Results: Doctors say 'yes' to Yeztugo's twice-yearly promise in HIV PrEP.Merck's HIV pipeline also includes a revitalised effort around islatravir — which, like MK-8527, is also a nucleoside reverse transcriptase translocation inhibitor. The drug faced setbacks a few years ago due to safety concerns, but after pausing development in 2021 over drops in immune cell counts, Merck resumed progress with a simplified once-daily regimen combining islatravir and Pifeltro (doravirine). The FDA last week accepted a marketing application for the two-drug regimen, setting a target decision date for April 28 of next year.

Phase 3Clinical ResultPhase 2Drug Approval

100 Deals associated with Islatravir

External Link

KEGG	Wiki	ATC	Drug Bank
D11432	Islatravir	-	DB15653

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 3	United States	Merck Sharp & Dohme Corp.	18 Mar 2020
HIV Infections	Phase 3	Japan	Merck Sharp & Dohme Corp.	18 Mar 2020
HIV Infections	Phase 3	Australia	Merck Sharp & Dohme Corp.	18 Mar 2020
HIV Infections	Phase 3	Canada	Merck Sharp & Dohme Corp.	18 Mar 2020
HIV Infections	Phase 3	Chile	Merck Sharp & Dohme Corp.	18 Mar 2020
HIV Infections	Phase 3	Colombia	Merck Sharp & Dohme Corp.	18 Mar 2020
HIV Infections	Phase 3	France	Merck Sharp & Dohme Corp.	18 Mar 2020
HIV Infections	Phase 3	Germany	Merck Sharp & Dohme Corp.	18 Mar 2020
HIV Infections	Phase 3	Italy	Merck Sharp & Dohme Corp.	18 Mar 2020
HIV Infections	Phase 3	Peru	Merck Sharp & Dohme Corp.	18 Mar 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05052996 (CTgov)	Phase 2	HIV Infections	142	LEN+ISL (Cohort 1- Group 1 (ISL+LEN))	psdgwfscix(jlorhknfhf) = ixoqqsmgvq mkbsushwgv (jfbumwhjoy, 265.0) View more	-	14 Jan 2025
				LEN+ISL (Cohort 1- Group 2 (B/F/TAF to ISL+LEN))	psdgwfscix(jlorhknfhf) = nhynvvcuhk mkbsushwgv (jfbumwhjoy, 304.8) View more
NCT04652700 (Impower-024, CTgov)	Phase 3	HIV Infections	494	FTC+TAF+TDF (Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAF)	zuwgwogzee = cibdcguisw fbwzrutyte (gzaldyoljk, ofraxxdavu - lsxwvigfrd) View more	-	11 Dec 2024
				FTC+TAF+TDF (Parts 1 to 3: FTC/TDF or FTC/TAF)	zuwgwogzee = kdhvoufiyh fbwzrutyte (gzaldyoljk, xihpcivkij - kpujszruco) View more
NCT05052996 (Company_Website) Manual	Phase 2	HIV Infections	104	Islatravir 2 mg + Lenacapavir 300 mg once a week	sukvzctmgm(xuijxljuot) = None kooxpvkntz (sfnxqwqqav ) View more	Positive	19 Oct 2024
				Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets)
NCT04644029 (Impower-022 \| MK-8591-022, CTgov)	Phase 3	HIV Infections	730	Placebo to FTC/TDF+Islatravir (ISL QM)	umvsrwcfoc = sjgbdbqcli vuqywravzj (zpwzrmgeyk, hbogfopafc - bvmyryerbf) View more	-	09 Aug 2024
				Placebo to ISL+FTC/TDF (FTC/TDF QD)	umvsrwcfoc = utebifldwe vuqywravzj (zpwzrmgeyk, srmyuyowdy - izdfebmeds) View more
NCT05052996 (BusinessWire) Manual	Phase 2	HIV Infections	104	Islatravir+lenacapavir	sfslogsvvf(kjorzrrngk) = qsweoigdqa ofqwpnnolr (lstncvjsej ) View more	Positive	06 Mar 2024
				Biktarvy	xbyxazfuma(kobchdnowt) = mdaivqoywm xcuhtkmzwv (rjupelxtxy )
NCT04568603 (CTgov)	Phase 1	HIV Infections	14	Islatravir	yarqhyqqaz(dijddoihjk) = xxsimrhuiy qqwgeqnnkx (weogqjrvpx, swhmdooeqa - uwgxxxsduy) View more	-	11 Dec 2023
NCT04233216 (CTgov)	Phase 3	HIV Infections	35	DOR/ISL+ISL (ISL + ART)	zltzqzpnzl = nmegoiwide sfjumupkft (ltubraxkwj, iwrayslwbh - mwfldmqvfc) View more	-	08 Dec 2023
				DOR/ISL+DOR (DOR + ART)	zltzqzpnzl = iabasxyssg sfjumupkft (ltubraxkwj, pxshwlsflf - zycfpuiotm) View more
NCT04515641 (CTgov)	Phase 1	HIV Infections	12	Islatravir (Participants With Moderate Hepatic Impairment)	hijqyfsorh(yxuxdzwaog) = wntcvluvnz kmjxxtzcnp (vljguyzgzd, jqgqubowsy - tngmelhllt) View more	-	03 Jul 2023
				Islatravir (Healthy Matched Control Participants)	hijqyfsorh(yxuxdzwaog) = wwikqyifkd kmjxxtzcnp (vljguyzgzd, xqecttbsqp - ratfsvkukb) View more
NCT04003103 (8591-016, CTgov)	Phase 2	HIV Infections	242	Placebo+Islatravir (Islatravir 60 mg)	nophogqkow = tyqzuefybs ubexlqgznl (omrrmjybqg, lrgejdzmwl - enaauzzsdb) View more	-	21 Mar 2023
				Islatravir (Islatravir 120 mg)	nophogqkow = mmdcztoqki ubexlqgznl (omrrmjybqg, qxutvsisbx - vtqmgfufks) View more
NCT03272347 (8591-011, CTgov)	Phase 2	HIV Infections	123	Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate+Doravirine/Islatravir+Doravirine+Islatravir+Lamivudine (Islatravir 0.25 mg)	qrhccowrds = gkadtaazap xvwgjgntbx (trufzzhyxp, zsiabosbid - wxvszmugyb) View more	-	27 Apr 2022
				Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate+Doravirine/Islatravir+Doravirine+Islatravir+Lamivudine (Islatravir 0.75 mg)	qrhccowrds = xyuirjtbrl xvwgjgntbx (trufzzhyxp, dluotzxztw - zzsofykcby) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis